Search the Newsreel

BridgeBio Pharma earnings up next amid encaleret milestone

BridgeBio Pharma is set to report its second-quarter earnings, with analysts expecting a loss of 60 cents per share on revenues of $222.2 million, driven by strong Attruby sales. Investors are keenly watching the commercial performance and the regulatory progress of encaleret, its experimental …

BridgeBio Pharma: Q2 Earnings Snapshot

BridgeBio Pharma Inc. reported a Q2 loss of $152.2 million, or 78 cents per share, missing analyst expectations of 64 cents per share. Despite the loss, the rare disease drug developer exceeded revenue forecasts, posting $243.7 million against an expected $222.6 million. The company's …

Has BridgeBio Pharma (BBIO) Run Too Far Ahead Of Its Valuation Narrative?

BridgeBio Pharma (BBIO) has seen significant share price gains, with a 30.61% return over 90 days and an 81.37% return over one year, closing at $84.48. While one valuation narrative suggests the stock is 237.9% overvalued with a fair value of $25, Simply Wall …

How Bridgebio Pharma Inc. (BBIO) Affects Rotational Strategy Timing

This article analyzes Bridgebio Pharma Inc. (BBIO) through quantitative research, highlighting a strong near-term sentiment with a long-term positive bias. It presents an exceptional risk-reward setup targeting a 13.9% gain, along with three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, …

BridgeBio Pharma, Inc. expected to post a loss of 58 cents a share - Earnings Preview

BridgeBio Pharma, Inc. is projected to report a loss of 58 cents per share in its upcoming earnings. This information is provided as an earnings preview by Reuters, distributed through TradingView News. The article suggests that readers can access more details on TradingView.

Will FDA Review of Encaleret and New Shelf Capacity Change BridgeBio Pharma's (BBIO) Narrative?

BridgeBio Pharma (BBIO) recently received FDA acceptance for its New Drug Application for encaleret, a potential first-in-class therapy for autosomal dominant hypocalcemia type 1, and filed two shelf registrations for US$2.21 billion in common stock. These developments could significantly alter BridgeBio's investment narrative by …

Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $111

Piper Sandler has reiterated its Buy rating on BridgeBio Pharma (BBIO.US) and maintained a target price of $111. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

BridgeBio Pharma (BBIO) Stock Looks Priced At A Premium Despite 148% Returns

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. BridgeBio Pharma stock has delivered a very strong 147.9% return over the past three years, yet its current checks lean expensive rather than clearly cheap. With a …

BridgeBio Pharma (BBIO) Wins FDA Review For Encaleret In ADH1

The FDA has accepted BridgeBio Pharma's New Drug Application (NDA) for encaleret, a potential first-in-class treatment for autosomal dominant hypocalcemia type 1 (ADH1). This acceptance initiates a formal review process with a set target action date. The stock has seen significant returns over the …

BridgeBio Pharma (NASDAQ:BBIO) CAO Maricel Apuli Sells 2,000 Shares

Maricel Apuli, CAO of BridgeBio Pharma (NASDAQ:BBIO), sold 2,000 shares for $160,120 under a pre-arranged trading plan, retaining 127,401 shares. The company's shares traded down 0.2% to $79.96, despite strong revenue growth of 66.8% year-over-year, as it missed EPS expectations. Analyst sentiment remains largely …

BridgeBio Pharma (NASDAQ: BBIO) CAO sells 2,000 shares in 10b5-1 trading plan

Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma (NASDAQ: BBIO), sold 2,000 shares of common stock on July 30, 2026, at a price of $80.06 per share. This transaction was conducted under a Rule 10b5-1 sales plan adopted on September 8, 2025. Following the …

BridgeBio Pharma (BBIO) After Its $2.21b Stock Filing Is It A Buy Or Priced In

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Why BridgeBio Pharma Stock Is Back In Focus BridgeBio Pharma (BBIO) is back on investor radars after filing two shelf registrations totaling about US$2.21b in …

Farallon group reports 10.7M BridgeBio (BBIO) shares, a 5.5% stake

Farallon Capital Management, L.L.C. and its related entities have filed an Amendment No. 1 to Schedule 13G, reporting a beneficial ownership of 10,743,063 shares of BridgeBio Pharma, Inc. (BBIO) common stock. This constitutes a 5.5% stake in the company, with the Reporting Persons holding …

BridgeBio schedules Aug. 10 webcast for results and updates

BridgeBio Pharma (Nasdaq: BBIO) announced it will release its second quarter 2026 financial results and business updates after market close on Monday, August 10, 2026. The company will host a conference call and live webcast at 4:30 pm ET on the same day for …

BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET

BridgeBio Pharma, Inc. announced that it will release its second quarter 2026 financial results and business update after the market closes on Monday, August 10, 2026. The company will host a conference call to discuss these results and program updates at 4:30 pm ET …

US10806XAH5 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the US10806XAH5 bond issued by BridgeBio Pharma, Inc., detailing its interest rate and payment schedule. The bond has a current coupon rate of 1.75%, and the next payment is scheduled for September 1, 2026. It highlights the …

1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree.

Key Points Additional FDA decisions could unlock new growth opportunities. Revenue is expected to nearly double this year. Profitability could finally arrive in 2027.10 stocks we like better than BridgeBio Pharma › BridgeBio Pharma(NASDAQ: BBIO) has already been one of biotech's biggest winners over …

BlackRock, Inc. Reduces BridgeBio Pharma Inc (BBIO) Stake -- Shares Trade 48% Below GF Value

BlackRock, Inc. significantly reduced its stake in BridgeBio Pharma Inc (BBIO) by selling over 4.4 million shares, representing a 31.49% change in its holdings. While BridgeBio's stock has seen a 7.53% gain since the transaction and exhibits strong growth metrics, its financial health remains …

BridgeBio Pharma (BBIO) Wins FDA NDA Acceptance, Is The Upside Already Priced In?

BridgeBio Pharma (BBIO) has received FDA New Drug Application acceptance for encaleret, following positive Phase 3 data and active launch preparations. Despite this clinical progress and strong share price performance over the last year, Simply Wall St's "Most Popular Narrative" suggests the stock is …

US10806XAK8 Bond Profile — Key Metrics

This article provides key metrics for the BridgeBio Pharma, Inc. 0.75% 01-FEB-2033 bond (US10806XAK8), traded on the Frankfurt Stock Exchange. It details the issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. The company, BridgeBio Pharma, Inc., is described as focusing …

BBIO|BridgeBio Pharma Inc|Price:79.906|Chg%:-3.634

The article provides a comprehensive stock analysis of BridgeBio Pharma Inc (BBIO), highlighting its strong fundamentals, high growth potential, and "Buy" ratings from analysts, with a target price of 105.16. Despite positive market performance, technical indicators suggest a sideways trading pattern between support and …

BridgeBio earnings on deck as company eyes four-product future

BridgeBio Pharma Inc. is set to report its second-quarter earnings, as the rare-disease biotech company transitions into a multi-product commercial operation. Analysts anticipate a loss of $0.60 per share on revenues of $222.2 million, with strong buy ratings and an implied 23% upside from …

US10806XAK8 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the BridgeBio Pharma, Inc. 0.75% bond due February 1, 2033, identified by US10806XAK8. It details that the current coupon rate is 0.75% and the next payment is scheduled for August 3, 2026. The bond's trading status on …

BridgeBio (BBIO) Stock Still Looks Pricey After FDA Filing Acceptance

BridgeBio Pharma (BBIO) has seen a significant 149.6% return over the past three years, driven by progress in its encaleret program and recent FDA filing acceptance. However, the stock's current Price/Sales ratio of 28.9x (compared to an industry average of 11.0x) suggests it is …

(BBIO) and the Role of Price-Sensitive Allocations

This article provides a detailed AI-driven analysis for Bridgebio Pharma Inc. (NASDAQ: BBIO), identifying a near-term strong sentiment with potential mid-term neutrality and long-term positive bias. It highlights a significant short setup with an exceptional risk-reward ratio and outlines three institutional trading strategies tailored …

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?

BridgeBio Pharma (BBIO) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare …

BridgeBio Pharma (BBIO) to Release Quarterly Earnings on Tuesday

BlackRock (BBIO holder) discloses 4.96% BridgeBio Pharma stake in amended 13G

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.96% beneficial ownership stake in BridgeBio Pharma, Inc., consisting of 9,733,762 common shares. The filing indicates BlackRock holds sole voting power over 9,472,242 shares and sole dispositive power over all 9,733,762 shares. This disclosure, …

BridgeBio Pharma Market Sentiment

This article analyzes market sentiment for BridgeBio Pharma (BBIO) based on analyst consensus, short interest, options flow, and insider activity. Key signals indicate a "Buy" consensus from analysts, declining short interest, and more calls than puts in options flow, suggesting a bullish outlook. Insider …

BBIO|BridgeBio Pharma Inc|Price:84.020|Chg%:+1.090

BridgeBio Pharma Inc. (BBIO) is a biopharmaceutical company focused on developing transformative medicines for genetic diseases, with a pipeline including treatments for conditions like transthyretin-mediated amyloidosis, achondroplasia, and Autosomal Dominant Hypocalcemia Type 1. The article provides an overview of the company, its financial details, …

BridgeBio Pharma, Inc. $BBIO Shares Purchased by Assetmark Inc.

Assetmark Inc. significantly increased its stake in BridgeBio Pharma, Inc. by 423.7% in Q1 2026, holding 20,790 shares valued at $1.54 million. Despite a larger-than-expected Q1 loss, the company reported strong revenue growth, and analyst sentiment remains largely positive with a "Moderate Buy" consensus. …

Affinity Asset Advisors LLC Has $11.14 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO

Affinity Asset Advisors LLC reduced its stake in BridgeBio Pharma by 53.1% in Q1 2026, selling 170,000 shares but still owning 150,000 shares valued at over $11 million. Despite this, BridgeBio Pharma, Inc. has a "Moderate Buy" consensus rating from analysts with an average …

Form S-3ASR BridgeBio Pharma Inc For: 24 July By Investing.com

This article from Investing.com reports that BridgeBio Pharma Inc. filed a Form S-3ASR on July 24th. The filing is a standard SEC registration statement that companies use to register securities for sale. The article provides minimal detail beyond the initial announcement.

BridgeBio Pharma, Inc. Revenue Breakdown – NASDAQ:BBIO

BridgeBio Pharma, Inc. (NASDAQ: BBIO) reported a total revenue of $502.08 million USD last year. Its Transformative Medicines segment was the top-performing division, contributing $362.37 million USD, an increase from $221.90 million USD the prior year. The United States market was the primary revenue …

Bridgebio Pharma Inc Files For Offering Of Up To 24.6 Million Common Shares By Selling Stockholders - SEC Filing

Bridgebio Pharma Inc. has filed with the SEC for an offering of up to 24.6 million common shares, which will be sold by existing stockholders. This information was reported in an SEC filing and relayed by Reuters. The news was highlighted on TradingView.

BridgeBio Pharma Inc (BBIO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of BridgeBio Pharma Inc (BBIO), identifying its major shareholders by proportion, including investment firms like Kohlberg Kravis Roberts & Co. L.P. and BlackRock Institutional Trust Company, N.A. It also categorizes shareholders by type (e.g., Investment Advisor, Hedge Fund) …